AXQ Capital
OCUL icon

AXQ Capital’s Ocular Therapeutix OCUL Stock Holding History

AXQ Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-18,640
Closed -$183K – 1327
2026
Q2 		$183K Sell
18,640
-12,015
-39% -$109K 0.02% 741
2026
Q1 		$260K Buy
+30,655
New +$292K 0.03% 643
2025
Q4 		– Sell
-11,517
Closed -$135K – 885
2025
Q3 		$135K Buy
11,517
+797
+7% +$9.5K 0.05% 492
2025
Q2 		$99.5K Buy
+10,720
New +$83.9K 0.03% 518
2023
Q2 		– Sell
-25,972
Closed -$137K – 485
2023
Q1 		$137K Buy
+25,972
New +$123K 0.05% 433

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $135M AUM 15.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Deltec Asset Management
Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

AXQ Capital's OCUL Position: Q3 2026 in Review

AXQ Capital sold out of Ocular Therapeutix (OCUL) in Q3 2026, closing a stake of 18,640 shares — an estimated $183K sold.

AXQ Capital first reported a position in OCUL in Q1 2023 and held it in 5 quarters. The position peaked at $260K in Q1 2026. 184 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • AXQ Capital reported no remaining Ocular Therapeutix position as of Q3 2026 after selling out during the quarter.
  • AXQ Capital sold 18,640 Ocular Therapeutix shares in Q3 2026, an estimated $183K.
  • AXQ Capital first reported a position in Ocular Therapeutix in Q1 2023 and held it in 5 quarters.
  • AXQ Capital's Ocular Therapeutix position peaked at $260K in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on AXQ Capital's 13F filing for Q3 2026, filed 12 Nov 2026.